In addition to close collaboration with CXCR7, using biophysical and biochemical methods, CXCR4 is found to form induced heterodimers with the cannabinoid receptor 2 (CB2) in human breast and prostate cancer cells (Coke et al., 2016). Here, ACKR3 is linked to prostate carcinoma.